CompletedNot Applicable

Combined HCC-MFCCC

100 participantsStarted 2004-01-01

Plain-language summary

Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * positive histology for cHCC-MFCCC, HCC, and MFCCC * complete clinical, surgical, pathological and follow-up data. Exclusion Criteria: * patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded. * patients operated for recurrent disease and/or with non-radical surgery * patients with missing data were also excluded

What they're measuring

Survival analysis

Timeframe: From 3 months after surgery up to 60 months after surgery

Trial details

NCT IDNCT03178409

SponsorUniversity of Milan

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2014-12-31

View on ClinicalTrials.gov More Liver Carcinoma trials